Research Analysts Offer Predictions for TARA FY2025 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Protara Therapeutics in a note issued to investors on Monday, March 17th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($1.62) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.09.

A number of other brokerages have also recently issued reports on TARA. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Thursday, March 6th. Finally, Guggenheim reaffirmed a "buy" rating and set a $20.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Protara Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $22.50.

Protara Therapeutics Trading Down 0.4 %

Shares of TARA stock traded down $0.02 on Wednesday, reaching $4.60. The company had a trading volume of 836,802 shares, compared to its average volume of 793,498. The stock has a market cap of $169.13 million, a PE ratio of -1.63 and a beta of 1.69. The company has a 50-day moving average of $4.29 and a 200-day moving average of $3.57. Protara Therapeutics has a 12 month low of $1.60 and a 12 month high of $10.48.

Institutional Investors Weigh In On Protara Therapeutics

Several institutional investors have recently added to or reduced their stakes in TARA. HBK Investments L P bought a new stake in shares of Protara Therapeutics in the fourth quarter valued at about $106,000. Squarepoint Ops LLC acquired a new stake in Protara Therapeutics in the 4th quarter valued at $110,000. Dimensional Fund Advisors LP bought a new stake in Protara Therapeutics during the fourth quarter worth about $111,000. Bailard Inc. acquired a new position in Protara Therapeutics during the fourth quarter valued at approximately $157,000. Finally, XTX Topco Ltd acquired a new position in shares of Protara Therapeutics during the 3rd quarter worth approximately $60,000. 38.13% of the stock is owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.